Lionel Couzi
Expertise in
1
conditions

Lionel Couzi

Transplant Surgery
Bordeaux, FR 
Expertise in
1
conditions
Bordeaux, FR 
OverviewLocationsClinical Research

Overview

Lionel Couzi is a Transplant Surgeon in Bordeaux, France. Mr. Couzi is highly rated in 1 condition, according to our data. His top areas of expertise are Atypical Hemolytic Uremic Syndrome (aHUS), End-Stage Renal Disease (ESRD), Paroxysmal Nocturnal Hemoglobinuria (PNH), Kidney Transplant, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 177 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Transplant Surgery
Gender
Male

Locations

Bordeaux, France
Other Locations
CHU Montpellier
Montpellier, France
Rouen, France
Clermont-ferrand, France
CH Roubaix
Roubaix, France
Marseille, France
Talence, France
France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection Episode
A Prospective, Observational Long-term Follow-up Trial of Kidney Transplant Patients Treated With Imlifidase or Plasma Exchange After an Active/Chronic Active Antibody-Mediated Rejection Episode
Enrollment Status: Terminated
Publish Date: May 28, 2025
Intervention Type: Drug
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Biological
Study Phase: Not Applicable
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Biological
Study Phase: Not Applicable
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Enrollment Status: Completed
Publish Date: March 08, 2023
Intervention Type: Biological
Study Phase: Not Applicable
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T
Enrollment Status: Completed
Publish Date: June 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

177 Total Publications

Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study.
Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study.
Journal: Transplantation direct
Published: June 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Couzi's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile